Company intelligence / Profile preview

Cytovant

China

Ownership: Private
Development stage: Other

Overview

Cytovant is developing TCR-T cell and dendritic cell (DC) therapies, with a focus on targets NY-ESO-1, WT-1, and PRAME, specifically tailored for patient populations in East Asia. These programs, licensed from Medigene and developed in collaboration, are in preclinical or early clinical stages; no late stage or pivotal clinical results have been reported yet.

Therapeutic areas: Oncology
Modalities: T cell receptor engineered T cell therapyDendritic cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

CVT-TCR-01

Discontinued

Partnerships

MedigeneSinovant Sciences

Beyond the preview

Go deeper on Cytovant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytovant.

Explore the full profile